Bristol Myers Squibb has received approval from the European Commission for the subcutaneous formulation of Opdivo® (nivolumab) for use across multiple solid tumor indications. This makes Opdivo the first and only PD-1 inhibitor approved for subcutaneous administration in the EU. The approval follows results from the Phase 3 CheckMate -67T clinical trial, which demonstrated the noninferiority of the subcutaneous version compared to its intravenous counterpart. The decision is applicable in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. This new formulation offers a quicker, 3- to 5-minute injection, enhancing the patient experience while maintaining consistent efficacy and safety.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.